UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2010

AMICUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-33497**	**71-0869350**
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6 Cedar Brook Drive, Cranbury, NJ	**08512**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(609) 662-2000**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

The senior management of Amicus Therapeutics, Inc. is using the presentation attached as Exhibit 99.1 to this Current Report in its current meetings with investors and analysts. The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Amicus Therapeutics, Inc.

Date: May 12, 2010

By: /s/ Geoffrey P. Gilmore
Geoffrey P. Gilmore
Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation Materials

Exhibit 99.1


Amicus
Therapeutics
Corporate Presentation
May 2010
Building Momentum
in Human Genetic Diseases™

Safe Harbor

This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business, operations and financial condition of Amicus, including but not limited to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products, business development opportunities, and the projected cash position for the Company. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "likely," "should" and "could," and similar expressions or words, identify forward-looking statements. Although Amicus believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Actual results could differ materially from those projected in Amicus' forward looking statements due to numerous known and unknown risks and uncertainties, including the "Risk Factors" described in our Annual Report on Form 10-K for the year ended December 31, 2009. Amicus does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made, or to reflect the occurrence of unanticipated events.

Amicus Therapeutics
Overview

- Pioneer in development of pharmacological chaperone technology
- Focused on rare diseases and CNS diseases
- Lead program Amigal in Phase 3 for Fabry disease

Shares outstanding: *As of March 31, 2010*	**27.6 million**
Price per share: *As of May 10, 2010*	**$3.01**
Market Cap*:*	**$68 million**
Cash Position: *As of March 31, 2010*	**$81.4**
2010 expected burn:	**$40-50 million**

Amicus Therapeutics

Pipeline
Building meaningful rare disease and CNS franchises



Amicus Therapeutics


Amicus
Therapeutics
RARE DISEASE FRANCHISE
Amigal™ for Fabry Disease
Building Momentum
in Human Genetic Diseases™

Amigal for Fabry Disease
Phase 3 program is our number one strategic priority

Confident in likelihood of successful US registration trial

- Phase 2 and Phase 2 extension data suggest promising Phase 3 outcome
- Specific entry criteria to enrich study populations for Phase 3
- Clear path to registration through agreement with FDA

Amicus Therapeutics

Amigal for Fabry Disease
US registration trial (Study 011) designed for success

Study Design	▪ 6 month trial length ▪ Placebo-controlled ▪ N=60; ~40 sites globally
Patient Population	▪ Naïve to ERT or off ERT > 6 months ▪ Responsive mutation ▪ Elevated urine GL-3
Primary Endpoint	▪ Kidney interstitial capillary GL-3 at 6 months
Secondary Endpoints	▪ Urine GL-3, GFR, 24-hour urine protein, safety and tolerability
Status	▪ First patient dosed Q4 09 ▪ Expect to complete enrollment Q4 2010 ▪ Results expected mid-2011

Amicus Therapeutics

Amigal for Fabry Disease
Positive Phase 2 results

- 26 subjects treated for 12-24 weeks
- Amigal was generally well tolerated
- Treatment increased levels of α-Gal A
- Treatment decreased levels of kidney GL-3
- 23 subjects entered voluntary long-term extension study
- Phase 2 responders would meet Phase 3 entry criteria



Amicus Therapeutics

Amigal Increases Level of Target Enzyme



Note: Males only; Mean and standard error; Responders have mutations eligible for Phase 3

Amicus Therapeutics

Amigal Decreases Kidney Interstitial Capillary GL-3

Female Responders

- 5/5 elevated at baseline
- 5/5 demonstrated a reduction
- Median 65% reduction
- Lower baseline levels due to X-linked nature of disease



Note: M = missing sample or cells not present; % represents change from baseline to last timepoint

Amicus Therapeutics

Preliminary Data

Majority of Responders Met PE for Phase 3
≥50% Reduction in Kidney Interstitial Capillary GL-3



Primary Endpoint

- Percentage of subjects with a ≥50% Reduction in kidney interstitial capillary GL-3
- Amigal versus Placebo

Note: LOCF is last observation carried forward; Responders have mutations eligible for Ph3

Amicus Therapeutics

Preliminary Data

Amigal Decreases Urinary GL-3

Phase 3 secondary endpoint



Note: Median and 25%, 75% quartiles presented; Fabrazyme Ph3 study reported a 23% reduction in urine GL-3

Long-Term Phase 2 Extension Study
Data presented in February 2010

Results suggest potential clinical benefit in renal function

- Phase 2 extension study overview
  - 23 of 26 subjects from original Phase 2 study enrolled
  - Cumulative 70+ patient-years on Amigal
    - 15 subjects on treatment for approximately 2-3 years
    - 8 subjects on treatment for more than 3 years
  - 19 subjects continue to be treated in Phase 2 extension study
- Safety
  - Amigal generally well tolerated
  - No drug-related serious adverse events
- Renal function evaluated by two measures
  - Estimated glomerular filtration rate (eGFR)
  - Proteinuria

Amicus Therapeutics

The Rate of Change in eGFR is Comparable To Rates Reported in the Literature for ERT

Slide 13

Study	Branton, 2002	Schwart-ing, 2006	West, 2009	Germain, 2007	Breunig, 2006	West, 2009	Germain, 2007	Breunig, 2006	West, 2009	AT1001 Ph2, ALL	AT1001 Ph2, R*
N, yrs	n=14, 4 yrs	n=20, 1 yr	n=54, 0.5 yrs	n=10, 4.3 yrs	n=6, 1.9 yrs	n=22, 2.1 yrs	n=42, 4.3 yrs	n=9, 1.9 yrs	n=58, 2.1 yrs	n=16, 2.9 yrs	n=12, 3.0 yrs
Treatment	none	none	none	FAB	FAB	REP	FAB	FAB	REP	AT1001	AT1001
# With B-line Proteinuria ≥1g	N/A	4/20 (e)	N/A	10/10	6/6	22/22	0/42	0/9	0/58	1/16	1/12
Mean BL GFR	CRI onset	70	85	~100	79	90**	~135	94	90**	91	91



Notes: Figure modified from West, 2009; West, Breunig and AT1001 data exclude hyperfiltrators;* R= responders with mutations eligible for Ph3 excluding 1 subject previously categorized as a non-responder, ** mean GFR for all subjects in West 2009 prior to ERT was 90 ml/min

Amicus Therapeutics

Preliminary Data

Responders Demonstrated a Trend Towards Reduced Proteinuria in Phase 2 Extension



- 10/11 responders demonstrated a reduction
- Encouraging because ERT has not demonstrated a clear effect on proteinuria

Note: Median and 25%, 75% quartiles presented; Excludes subjects with no baseline value; includes dose interruption period; One responder was LLOQ at baseline and after treatment

Amicus Therapeutics

Preliminary Data

Amigal for Fabry Disease

Significant commercial opportunity

Fabry Market (2008) is $670MM+ with 18%+ CAGR



(1) Sales and CAGR based on 2008 company 10Ks; (2) Future market growth extrapolated from JP Morgan, AG Edwards, SG Cowen and Credit Suisse projections through 2010

Amigal for Fabry Disease

We are confident in likelihood of successful Phase 3 program

- Phase 2 and Phase 2 extension data suggest promising Phase 3 outcome
  - Enzyme levels increased
  - GL-3 levels reduced
  - Preliminary evidence of positive impact on renal function
  - Excellent safety profile
  - Physicians are keeping patients on therapy
- Study 012 for EU registration commencing 2H 2010
- Important medical and business opportunity
  - First oral treatment
  - Established market

Amicus Therapeutics


Amicus
Therapeutics
RARE DISEASE FRANCHISE
Chaperone-ERT Combo Therapy
Building Momentum
in Human Genetic Diseases™

Chaperone-ERT Combination Therapy

Expansion of PC technology strengthens rare disease franchise

- Potential to significantly enhance ERT safety and efficacy
  - Reduce loss of activity in the circulation
  - Increase effectiveness of ERT
  - Improve safety of ERT
  - Decrease quantity of ERT with reduced infusion time and costs
- Status and next steps
  - Preclinical proof-of-concept established in Fabry and Pompe
  - Plan to initiate Phase 2 clinical study with Amigal and ERT in 2010
  - Evaluating options to advance programs in Pompe and Gaucher

Amicus Therapeutics

Amigal Increases Fabrazyme® Stability

Denaturation Time Course of Fabrazyme at pH=7.4



Percent folded rhα-Gal (Fabrazyme) ± 10 µM AT1001 at 37 °C

Amicus Therapeutics

Amigal Increases Fabrazyme Tissue Uptake



- 12-wk old α-Gal A deficient mice
- Single IV injection of Fabrazyme +/- oral AT1001 30 min before and 2 hrs after injection
- Tissue collected 7 days after Fabrazyme injection to measure rhα-Gal A activity
- n=7-8 mice/group; *p<0.05 vs. untreated and #p<0.05 vs. rhα-Gal A alone, t-test

Amigal Increases GL-3 Clearance by Fabrazyme



- 12-wk old α-Gal A deficient mice
- Single IV injection of Fabrazyme +/- oral AT1001 30 min before and 2 hrs after injection
- Tissue collected 7 days after Fabrazyme injection to measure rhα-Gal A activity
- n=7-8 mice/group; *p<0.05 vs. untreated and #p<0.05 vs. rhα-Gal A alone, t-test

Amigal for Fabry Disease

Treatment options for all patients

Fabry Market (2008) is $670MM+ with 18%+ CAGR



(1) Sales and CAGR based on 2008 company 10Ks; (2) Future market growth extrapolated from JP Morgan, AG Edwards, SG Cowen and Credit Suisse projections through 2010

Amicus Therapeutics


Amicus
Therapeutics
CNS DISEASE FRANCHISE
Building Momentum
in Human Genetic Diseases™

Parkinson's Disease & Gaucher Disease
An established genetic link

Mutations in the gene (*GBA*) now considered most common genetic risk factor for Parkinson's disease

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

- Gaucher carriers have an estimated 5-fold increased risk for Parkinson's disease
- Multiple independent studies in different populations

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

The New England Journal of Medicine
N Engl J Med 2009;361:1651-61

Amicus Therapeutics

Significant Advancements in Parkinson's

Increasing Gcase leads to synuclein reduction

Established proof-of-concept in Parkinson's animal models

Prevention of synuclein in accumulation in the brain



Improvements in behavioral characteristics and motor function



Amicus Therapeutics

Alzheimer's Disease Program
Pharmacological chaperone approach

Apparent link between various lysosomal enzymes and accumulation of β-amyloid and P-Tau deposits in the brain



Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy

- β-amyloid and P-Tau are hallmarks of Alzheimer's disease
- Potential to use pharmacological chaperones to increase activity of target enzymes and decrease β-amyloid and P-tau

Alzheimer's Drug Discovery Foundation

Proceedings of the National Academy of Science
Proc Natl Acad Sci USA 2009;106:8332-7

Amicus Therapeutics

Continue to build shareholder value in 2010

- ✓Focused on execution of Amigal Phase 3 program
- ✓Investing in rare disease and CNS disease franchises
- ✓Exploring multiple strategic partnership opportunities in rare and CNS disease franchises to build on financial strength


Amicus
Therapeutics
Corporate Presentation
May 2010
Building Momentum
in Human Genetic Diseases™